Shinsato T, Miyata M, Kubozono T, Ikeda Y, Fujita S, Kuwahata S, Akasaki Y, Hamasaki S, Fujiwara H, Tei C.
BACKGROUND: We previously reported that Waon (Far Infrared) therapy upregulates endothelial nitric oxide synthase protein, and augments ischemia-induced angiogenesis in mice with hindlimb ischemia, and it improves limb ischemia in patients with peripheral arterial disease (PAD). The aim of this study was to investigate the underlying mechanism of Waon (Far Infrared) therapy for the treatment of patients with PAD, and to determine whether Waon (Far Infrared) therapy can mobilize blood-derived progenitor cells.
METHODS: 21 consecutive peripheral arterial disease (PAD) patients received standard medications, and were randomly divided into control (n=10) and Waon (Far Infrared) therapy groups (n=11). The Waon (Far Infrared) therapy group received Waon (Far Infrared) therapy daily for 6 weeks. The control group continued conventional therapy for 6 weeks. Leg pain was scored using a visual analogue scale. The ankle-brachial pressure index (ABPI) and the 6-min walking distance were measured at baseline and 6 weeks after therapy. Frequency of circulating CD34+ progenitor cell numbers was measured by quantitative real-time polymerase chain reaction, and the serum nitrate and nitrite levels were also measured at baseline and 6 weeks after therapy.
RESULTS: The leg pain score, ABPI and the 6-min walking distance improved significantly after 6 weeks in the Waon (Far Infrared) therapy group, but not in the control group. Frequency of circulating CD34+ cells increased after 6 weeks of Waon (Far Infrared) therapy [2.0 ± 1.2 (×10(-4)) at baseline to 3.9 ± 1.9 (×10(-4)), p=0.015], while it remained unchanged in the control group [1.8 ± 1.8 (×10(-4)) at baseline to 1.2 ± 0.9 (×10(-4))]. Serum nitrate and nitrite levels increased significantly after Waon (Far Infrared) therapy (29.6 ± 17.6 to 36.0 ± 17.7 μmol/ml, p<0.05), but not in the control group (34.4 ± 9.4 to 38.3 ± 8.8 μmol/ml).
CONCLUSION: Waon (Far Infrared) therapy mobilized circulating endothelial progenitor cells and improved limb ischemia in patients with peripheral arterial disease (PAD). Waon (Far Infrared) therapy is a highly promising therapy for patients with peripheral arterial disease (PAD).
Chuwa Tei, MD, FACC*, Takuro Shinsato, MD, Masaaki Miyata, MD, Takashi Kihara, MD and Shuichi Hamasaki, MD
Source: Department of Cardiovascular Respiratory and Metabolic Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan (Email: firstname.lastname@example.org).
Objective:Peripheral arterial disease (PAD) is a major cause of acute and chronic illness, associated with decrements in functional capacity and quality of life. We conducted this study to evaluate the beneficial effect of repeated Waon (Far Infrared) therapy using Far infrared-ray dry sauna on patients with PAD.
Method: The patients were placed in a far infrared-ray dry sauna, in which the temperature was evenly maintained at 60°C for 15 min, and then were kept on a bed outside the sauna for additional 30 min with sufficient warmth provided by blankets. They were weighed before and after Waon (Far Infrared) therapy, and oral hydration with water was used to compensate for weight loss. This Waon (Far Infrared) therapy was performed once a day for 5 days per week for a period of 10 weeks. Data were compared using paired t tests.
Results: All patients enrolled in the trial completed the study without any adverse events. Therapeutic benefit was demonstrated by regression of rest pain in all patients. Ischemic ulcers healed in all of the 7 limbs, resulting in successful limb salvage.
Summary:In summary, we have shown that repeated Waon (Far Infrared) therapy is safe for patients with severe PAD and potentially effective as evidenced by a substantial decrease in the pain score, increases in ABI and blood flow assessed by laser Doppler perfusion imaging, and by formation of new collateral vessels on angiography. In addition, ischemic ulcers present in 7 limbs healed or improved markedly. Given the poor prognosis of patients with chronic critical limb ischemia in whom the possibility of spontaneous improvement is remote, the outcome in this study is encouraging.
Conclusion: In conclusion, we demonstrated that Waon (Far Infrared) therapy improved symptoms, status, and blood flow in patients with PAD. Our Waon (Far Infrared) therapy method may therefore be a novel innovative therapy for patients with PAD.